Psoriasis Drugs Market - Global Forecast 2026-2032

The Psoriasis Drugs Market is projected to reach USD 18.54 Billion in 2026. It is expected to continue growing at a CAGR of 10.85%, reaching USD 34.50 Billion by 2032.

Psoriasis drugs are moving from broad immunosuppression toward precision dermatology, with treatment decisions increasingly shaped by disease severity, comorbid psoriatic arthritis, prior biologic exposure, route of administration, payer access, and patient preference. Psoriasis is recognized by the World Health Organization as a chronic, immune-mediated, noncommunicable disease with systemic impact, and peer-reviewed epidemiology consistently places global prevalence at roughly 2% to 3%, with meaningful variation by geography, ancestry, age, and diagnostic access.

The psoriasis therapeutics landscape spans topical corticosteroids and vitamin D analogs, phototherapy-adjacent care, oral systemic therapies such as methotrexate, cyclosporine, apremilast, deucravacitinib, and targeted biologics directed at TNF-alpha, IL-17, IL-12/23, and IL-23 pathways. Demand is being driven by higher diagnosis rates, expanding biologic eligibility, biosimilar adoption, longer-term safety evidence, and patient expectations for durable skin clearance, lower treatment burden, and convenient dosing.

Transformative Shifts in the Psoriasis Treatment Landscape

The competitive landscape is being reshaped by interleukin-focused biologics that have raised clinical expectations from symptom control to high levels of skin clearance, including PASI 90 and PASI 100 outcomes reported in pivotal trials. IL-23 and IL-17 inhibitors have strengthened the standard of care for moderate-to-severe plaque psoriasis, while oral innovation, including TYK2 inhibition, is widening options for patients who prefer noninjectable therapies or are not ready for biologic treatment.

At the same time, biosimilars are altering pricing dynamics in TNF-alpha therapy and encouraging payers to revisit formulary design, step therapy, and prior authorization criteria. Dermatology practices are adapting to more complex sequencing decisions as clinicians balance efficacy, infection risk, inflammatory bowel disease considerations, psoriatic arthritis activity, cardiometabolic comorbidities, pregnancy planning, and long-term adherence.

Cumulative Impact of Artificial Intelligence on Psoriasis Drugs

Artificial intelligence is becoming a practical force in psoriasis drug development, commercialization, and care delivery. In research, AI-enabled image analysis can support more objective severity assessment using clinical photography, while machine learning models are being explored to stratify patients by treatment response, comorbidity risk, flare probability, and adherence patterns. These tools may reduce variability in PASI scoring and improve trial enrichment when validated against dermatologist-led assessments.

For manufacturers and healthcare systems, AI can improve pharmacovigilance signal detection, medical information workflows, real-world evidence generation, claims analytics, and patient support personalization. However, adoption must remain clinically governed because psoriasis datasets can underrepresent darker skin tones and underserved populations, creating bias risks in diagnostic tools, severity algorithms, and digital triage platforms.

Key Regional Insights Across Major Psoriasis Drug Markets

North America remains a leading region for psoriasis drugs because of high biologic utilization, strong specialist access, advanced payer management, and rapid uptake of FDA-approved targeted therapies in the United States and Canada. Europe combines broad dermatology expertise with stringent health technology assessment, making reimbursement evidence, comparative effectiveness, treatment guidelines, and biosimilar value central to access across the European Union and the United Kingdom.

Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia improve specialty care capacity and increase access to biologics and oral targeted therapies, although affordability, reimbursement depth, and urban-rural dermatology access vary widely. Latin America, led by Brazil and Mexico, shows rising demand for advanced therapies but remains sensitive to public procurement, reimbursement delays, and out-of-pocket costs. The Middle East, particularly GCC markets, is investing in specialty care infrastructure and centralized access pathways, while Africa continues to face diagnosis gaps, uneven dermatology access, and limited availability of high-cost biologics outside major urban centers.

Key Group Insights for Psoriasis Drug Access and Growth

Within ASEAN, psoriasis drug demand is influenced by growing dermatology networks, private hospital expansion, medical tourism in selected markets, and variable reimbursement across Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. The GCC benefits from high healthcare investment, centralized procurement, national insurance reforms, and increasing specialist availability, supporting access to biologics for eligible moderate-to-severe patients.

The European Union is shaped by coordinated regulatory standards, country-level reimbursement negotiations, clinical guideline adoption, and strong biosimilar policies that influence pricing and access. BRICS markets represent a major long-term opportunity because of large patient pools, expanding local pharmaceutical capabilities, and rising specialist care capacity, though affordability and public funding remain decisive. G7 countries continue to set clinical, regulatory, and pharmacovigilance benchmarks, while NATO member markets overlap substantially with advanced North American and European systems where supply resilience, quality standards, reimbursement scrutiny, and medicine security are prominent.

Key Country Insights in Psoriasis Drug Commercialization

The United States is the most innovation-intensive psoriasis drug market, supported by FDA approvals, specialty pharmacy channels, dermatology biologic experience, and broad use of targeted therapies, though payer controls strongly influence treatment sequencing. Canada emphasizes evidence-based reimbursement and provincial access decisions, while Mexico and Brazil show increasing demand for advanced dermatology care amid public-sector budget constraints, uneven access, and affordability pressure.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are characterized by strong guideline adoption, health technology assessment, structured reimbursement, and growing biosimilar use, while Russia faces more localized access, registration, and procurement dynamics. China is expanding access through regulatory modernization, accelerated review pathways, and national reimbursement mechanisms; India remains highly price-sensitive with growing specialist adoption in urban centers; Japan and South Korea maintain sophisticated dermatology markets with strong clinical governance; and Australia benefits from structured reimbursement through established public funding mechanisms that support eligible patients with moderate-to-severe disease.

Actionable Recommendations for Psoriasis Drug Industry Leaders

Industry leaders should prioritize differentiated clinical value rather than relying solely on class participation. Evidence packages should address high skin clearance, durability, speed of onset, long-term safety, psoriatic arthritis relevance, quality-of-life improvement, and real-world persistence. Manufacturers also need stronger market access planning that anticipates biosimilar competition, step edits, prior authorization, and payer demand for comparative outcomes.

Organizations should invest in inclusive clinical trials, skin-of-color evidence, patient support programs, digital adherence tools, and education that reduces treatment discontinuation and underdiagnosis. Regional strategies must reflect reimbursement realities: value dossiers for Europe, payer navigation in North America, affordability models in emerging markets, tender readiness in public procurement systems, and evidence generation that supports both clinical confidence and equitable access.

Research Methodology for Psoriasis Drugs Analysis

This executive summary is based on a secondary-research framework using publicly available and verifiable sources, including regulatory agency information, peer-reviewed dermatology literature, clinical trial publications, treatment guidelines, epidemiology references, pharmacovigilance updates, and health technology assessment patterns. Sources considered include organizations such as the World Health Organization, U.S. Food and Drug Administration, European Medicines Agency, national dermatology associations, and published clinical evidence on psoriasis biologics, biosimilars, oral systemic therapies, and targeted immune modulators.

The analysis integrates therapeutic class dynamics, regional access conditions, policy factors, technology trends, and real-world care considerations. It avoids unsupported market-size claims and emphasizes evidence-backed drivers such as psoriasis prevalence, biologic innovation, biosimilar uptake, reimbursement controls, comorbidity management, and AI-enabled clinical and commercial applications.

Conclusion: Future Direction of the Psoriasis Drugs Market

The psoriasis drugs market is entering a more competitive, evidence-driven phase where durable clearance, convenience, safety, affordability, and access are all decisive. Targeted biologics and oral immune modulators have transformed expectations for moderate-to-severe plaque psoriasis, while biosimilars, health technology assessment, and payer policies are reshaping commercial strategy.

Future success will depend on proving differentiated value across diverse patient populations and healthcare systems. Organizations that combine strong clinical evidence, equitable access planning, AI-enabled insights, inclusive real-world data, and disciplined regional execution will be best positioned to lead in the evolving psoriasis therapeutics landscape.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Psoriasis Drugs Market, by Drug Class

7.1. Introduction
7.2. Biologics
7.2.1. IL 17 Inhibitors
7.2.2. IL 23 Inhibitors
7.2.3. TNF Inhibitors
7.3. Small Molecules
7.3.1. JAK Inhibitors
7.3.2. PDE4 Inhibitors

8. Psoriasis Drugs Market, by Route Of Administration

8.1. Introduction
8.2. Injectable
8.2.1. Intravenous
8.2.2. Subcutaneous
8.3. Oral
8.3.1. Capsules
8.3.2. Suspensions
8.3.3. Tablets
8.4. Topical
8.4.1. Creams
8.4.2. Foams
8.4.3. Gels
8.4.4. Ointments

9. Psoriasis Drugs Market, by Psoriasis Type

9.1. Introduction
9.2. Erythrodermic Psoriasis
9.3. Guttate Psoriasis
9.4. Inverse Psoriasis
9.5. Nail Psoriasis
9.6. Plaque Psoriasis
9.7. Pustular Psoriasis
9.8. Scalp Psoriasis

10. Psoriasis Drugs Market, by Patient Type

10.1. Introduction
10.2. Adults
10.3. Geriatric
10.4. Pediatric

11. Psoriasis Drugs Market, by Distribution Channel

11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
11.5. Specialty Pharmacies

12. Psoriasis Drugs Market, by Treatment Setting

12.1. Introduction
12.2. Home-Based Treatment
12.3. Hospital-Based Care
12.4. Specialty Dermatology Clinics

13. Psoriasis Drugs Market, by Region

13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East

14. Psoriasis Drugs Market, by Group

14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC

15. Psoriasis Drugs Market, by Country

15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain

16. Competitive Landscape

16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025

17. Company Profiles

17.1. AbbVie Inc.
17.2. Almirall S.A.
17.3. Amgen Inc
17.4. AstraZeneca PLC
17.5. Bausch Health Companies Inc.
17.6. Biogen Inc.
17.7. Boehringer Ingelheim International GmbH
17.8. Bristol-Myers Squibb Company
17.9. Celltrion, Inc.
17.10. Dermavant Sciences Ltd.
17.11. Eli Lilly and Company
17.12. Fresenius Kabi AG
17.13. GlaxoSmithKline plc
17.14. Glenmark Pharmaceuticals Ltd.
17.15. Incyte Corporation
17.16. Johnson & Johnson Services, Inc.
17.17. LEO Pharma A/S
17.18. Lupin Limited
17.19. Merck & Co., Inc.
17.20. Mitsubishi Tanabe Pharma Corporation
17.21. Novartis AG
17.22. Pfizer Inc.
17.23. Samsung Bioepis Co., Ltd.
17.24. Sanofi S.A.
17.25. Sun Pharmaceutical Industries Ltd
17.26. Takeda Pharmaceutical Company Limited
17.27. UCB S.A.
17.28. Viatris Inc.

List of Figures

FIGURE 1. GLOBAL PSORIASIS DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PSORIASIS DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PSORIASIS DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PSORIASIS DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL PSORIASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL PSORIASIS DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

List of Tables

TABLE 1. GLOBAL PSORIASIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL IL 17 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL IL 17 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL IL 17 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL IL 23 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL IL 23 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL IL 23 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL TNF INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL TNF INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL JAK INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL JAK INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL JAK INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SUSPENSIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SUSPENSIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SUSPENSIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL CREAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CREAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL CREAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL FOAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL FOAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL FOAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL GELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL GELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL GELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL OINTMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL OINTMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL OINTMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ERYTHRODERMIC PSORIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ERYTHRODERMIC PSORIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ERYTHRODERMIC PSORIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL GUTTATE PSORIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL GUTTATE PSORIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL GUTTATE PSORIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL INVERSE PSORIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL INVERSE PSORIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL INVERSE PSORIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL NAIL PSORIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL NAIL PSORIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL NAIL PSORIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL PUSTULAR PSORIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL PUSTULAR PSORIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL PUSTULAR PSORIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SCALP PSORIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL SCALP PSORIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL SCALP PSORIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL ADULTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL HOME-BASED TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL HOME-BASED TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL HOME-BASED TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL HOSPITAL-BASED CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL HOSPITAL-BASED CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL HOSPITAL-BASED CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL SPECIALTY DERMATOLOGY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL SPECIALTY DERMATOLOGY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL SPECIALTY DERMATOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 130. EUROPE PSORIASIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. EUROPE PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 132. EUROPE PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 133. EUROPE PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 134. EUROPE PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 135. EUROPE PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 136. EUROPE PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 137. EUROPE PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 138. EUROPE PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 139. EUROPE PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 140. EUROPE PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 141. EUROPE PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 147. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 148. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 149. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 150. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 151. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 152. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 153. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 157. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 158. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 159. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 160. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 161. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 162. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 163. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 164. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 166. AFRICA PSORIASIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 167. AFRICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 168. AFRICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 169. AFRICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 170. AFRICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 171. AFRICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 172. AFRICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 173. AFRICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 174. AFRICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 175. AFRICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 176. AFRICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 177. AFRICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 180. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 181. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 182. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 183. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 184. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 185. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 186. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 187. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 188. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 189. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 190. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 191. NATO PSORIASIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 192. NATO PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 193. NATO PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 194. NATO PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 195. NATO PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 196. NATO PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 197. NATO PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 198. NATO PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 199. NATO PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 200. NATO PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 201. NATO PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 202. NATO PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 203. G7 PSORIASIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 204. G7 PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 205. G7 PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 206. G7 PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 207. G7 PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 208. G7 PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 209. G7 PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 210. G7 PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 211. G7 PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 212. G7 PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 213. G7 PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 214. G7 PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 215. BRICS PSORIASIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 216. BRICS PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 217. BRICS PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 218. BRICS PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 219. BRICS PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 220. BRICS PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 221. BRICS PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 222. BRICS PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 223. BRICS PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 224. BRICS PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 225. BRICS PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 226. BRICS PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 239. ASEAN PSORIASIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 240. ASEAN PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 241. ASEAN PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 242. ASEAN PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 243. ASEAN PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 244. ASEAN PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 245. ASEAN PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 246. ASEAN PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 247. ASEAN PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 248. ASEAN PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 249. ASEAN PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 250. ASEAN PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 251. GCC PSORIASIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 252. GCC PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 253. GCC PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 254. GCC PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 255. GCC PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 256. GCC PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 257. GCC PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 258. GCC PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 259. GCC PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 260. GCC PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 261. GCC PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 262. GCC PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 263. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 264. CHINA PSORIASIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 265. CHINA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 266. CHINA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 267. CHINA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 268. CHINA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 269. CHINA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 270. CHINA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 271. CHINA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 272. CHINA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 273. CHINA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 274. CHINA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 275. CHINA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 276. UNITED STATES PSORIASIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 277. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 278. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 279. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 280. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 281. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 282. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 283. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 284. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 285. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 286. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 287. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 288. JAPAN PSORIASIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 289. JAPAN PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 290. JAPAN PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 291. JAPAN PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 292. JAPAN PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 293. JAPAN PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 294. JAPAN PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 295. JAPAN PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 296. JAPAN PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 297. JAPAN PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 298. JAPAN PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 299. JAPAN PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 300. INDIA PSORIASIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 301. INDIA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 302. INDIA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 303. INDIA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 304. INDIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 305. INDIA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 306. INDIA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 307. INDIA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 308. INDIA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 309. INDIA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 310. INDIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 311. INDIA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 312. GERMANY PSORIASIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 313. GERMANY PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 314. GERMANY PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 315. GERMANY PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 316. GERMANY PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 317. GERMANY PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 318. GERMANY PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 319. GERMANY PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 320. GERMANY PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 321. GERMANY PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 322. GERMANY PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 323. GERMANY PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 324. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 326. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 327. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 328. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 329. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 330. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 331. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 332. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 333. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 334. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 335. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 336. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 337. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 338. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 339. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 340. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 341. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 342. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 343. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 344. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 345. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 346. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 347. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 348. FRANCE PSORIASIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 349. FRANCE PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 350. FRANCE PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 351. FRANCE PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 352. FRANCE PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 353. FRANCE PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 354. FRANCE PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 355. FRANCE PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 356. FRANCE PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 357. FRANCE PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 358. FRANCE PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 359. FRANCE PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 360. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 361. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 362. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 363. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 364. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 365. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 366. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 367. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 368. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2017-2032 (USD MILLION)
TABLE 369. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 370. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 371. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2017-2032 (USD MILLION)
TABLE 372. ITALY PSORIASIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 373. ITALY PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 374. ITALY PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 375. ITALY PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 376. ITALY PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 377. ITALY PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 378. ITALY PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 379. ITALY PSORIASIS D

Companies Mentioned

AbbVie Inc.
Almirall S.A.
Amgen Inc
AstraZeneca PLC
Bausch Health Companies Inc.
Biogen Inc.
Boehringer Ingelheim International GmbH
Bristol‑Myers Squibb Company
Celltrion, Inc.
Dermavant Sciences Ltd.
Eli Lilly and Company
Fresenius Kabi AG
GlaxoSmithKline plc
Glenmark Pharmaceuticals Ltd.
Incyte Corporation
Johnson & Johnson Services, Inc.
LEO Pharma A/S
Lupin Limited
Merck & Co., Inc.
Mitsubishi Tanabe Pharma Corporation
Novartis AG
Pfizer Inc.
Samsung Bioepis Co., Ltd.
Sanofi S.A.
Sun Pharmaceutical Industries Ltd
Takeda Pharmaceutical Company Limited
UCB S.A.
Viatris Inc.

Table Information

Report Attribute	Details
No. of Pages	190
Published	August 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 18.54 Billion
Forecasted Market Value ( USD ) by 2032	$ 34.5 Billion
Compound Annual Growth Rate	10.8%
Regions Covered	Global
No. of Companies Mentioned	29

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3184EUR$3,545USD£2,720GBP €3538EUR$3,939USD£3,022GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4817EUR$5,363USD£4,115GBP €5352EUR$5,959USD£4,572GBP

Transformative Shifts in the Psoriasis Treatment Landscape

Cumulative Impact of Artificial Intelligence on Psoriasis Drugs

Key Regional Insights Across Major Psoriasis Drug Markets

Key Group Insights for Psoriasis Drug Access and Growth

Key Country Insights in Psoriasis Drug Commercialization

Actionable Recommendations for Psoriasis Drug Industry Leaders

Research Methodology for Psoriasis Drugs Analysis

Conclusion: Future Direction of the Psoriasis Drugs Market

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Psoriasis Therapeutics Market - Global Forecast 2026-2032

Middle East Psoriasis Drugs Market Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030

Autoimmune Disease Drugs Market - Global Forecast 2026-2032

Psoriasis Treatment - Global Strategic Business Report

Psoriasis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)